Health from the Sun: The Total EFA High Lignan Formula with Evening Primrose Oil shipped Jan. 2. The new liquid contains flax oil providing, per serving, 5,872 mg omega-3 ALA, plus 12 mg lignans from flax particulate, and borage and evening primrose oils, providing 288 mg omega-6 GLA. The product, sold in independent and chain health food stores and in mass outlets, is packaged in 8 oz. bottles that retail for about $8.99. It can be used in blender drinks, poured over salads, or used in any food preparation that is not heated. The launch adds to the company's other flax seed oil-based products ("The Tan Sheet" Nov. 11, 1996, In Brief)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
